Advertisement

Topics

Hikma Interim Results Statement On Its ANDA For Generic Advair Diskus (VR315)

20:00 EDT 16 Aug 2017 | BioSpace

Chippenham, UK 17 August 2017: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading device and formulation business for inhaled airways products, today confirms the statement made by its partner Hikma Pharmaceuticals PLC (Hikma) in its interim results statement in respect of its abbreviated new drug application (ANDA) filing for a US generic version of....

Original Article: Hikma Interim Results Statement On Its ANDA For Generic Advair Diskus (VR315)

NEXT ARTICLE

More From BioPortfolio on "Hikma Interim Results Statement On Its ANDA For Generic Advair Diskus (VR315)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...